Compare Mesoblast Limited (MESO) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Xpeng Inc - ADR — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while Xpeng Inc - ADR trades at $13.22 (market cap $12.96B). The key difference: Xpeng Inc - ADR is far larger — about 6× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals.
| MESO | XPEV | |
|---|---|---|
Market Cap | $2.17B | $12.96B |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $28.07 |
52-Week Low | $12.88 | $12.09 |
Enterprise Value | $2.17B | $15.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
XPEV stock trades at $13.22, down 2.33% on the day, with a neutral technical outlook. The company reported revenue of $76.72 billion in 2025, but net losses persist, though the margin improved to -1.49%. Recent news highlights overseas expansion with the L03 SUV launch in Munich and progress in autonomous driving technology. Analyst consensus is bullish with a $17.00 price target, but cash flow volatility and competitive pressures remain concerns.
The outlook for XPEV hinges on execution of global expansion and new model launches to drive profitability. Investment opportunity lies in market share gains and technology leadership in EVs and AI, but risks include intense competition, reliance on Chinese market dynamics, and ongoing cash burn. The stock offers growth potential if the company can sustain revenue growth and narrow losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
